Vitality Watch

Dossier pubmed observational 25-aug-2026
Human cohort, case-control, or epidemiological association

Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m: A Target Trial Emulation.

Key claim: In adults with type 2 diabetes and BMI below 27 kg/m², GLP-1 receptor agonist use was consistently associated with reduced heart failure risk compared to DPP-4 inhibitors, SGLT2 inhibitors, and usual care.

Abstract

AIMS: Cardiorenal evidence for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) derives mainly from trials in overweight or obesity; data in adults with Type 2 diabetes (T2D) and body mass index (BMI) below 27 kg/mare limited. MATERIALS AND METHODS: We emulated a target trial in the TriNetX US Collaborative Network (index dates 2020 to 2026; maximum follow-up 24 months). Adults with T2D and BMI < 27 kg/mnewly initiating non-tirzepatide GLP-1 RAs were compared with new users of dipeptidyl peptidase-4 inhibitors (DPP-4i), sodium-glucose cotransporter-2 inhibitors (SGLT2i) or usual care. Comparisons used separate 1:1 propensity score matching. The primary outcome was all-cause mortality. RESULTS: After matching, 7389, 8969 and 8610 GLP-1 RA users were matched to DPP-4i, SGLT2i and usual care. Versus DPP-4i, GLP-1 RA was associated with lower all-cause mortality (hazard ratio [HR] 0.61; 95% confidence interval [CI] 0.52-0.71), major adverse cardiovascular events (MACE; HR 0.83; 95% CI 0.71-0.98) and coded heart failure (HR 0.71; 95% CI 0.60-0.85). Versus SGLT2i, MACE (HR 0.81; 95% CI 0.69-0.95) and coded heart failure (HR 0.56; 95% CI 0.47-0.65) were lower, but all-cause mortality was not (HR 0.89; 95% CI 0.76-1.05). Gastroparesis was more frequent versus DPP-4i. CONCLUSION: In people with T2D and BMI < 27 kg/m, GLP-1 RA use was associated with lower coded heart failure risk across all three comparisons, the most consistent finding. The lower all-cause mortality association versus DPP-4i and usual care, absent versus SGLT2i, should be interpreted cautiously as likely reflecting residual confounding rather than a benefit of this magnitude.

Why this matters

This target trial emulation adds a heart-failure association in adults with type 2 diabetes and BMI <27 kg/m² [human-observational], extending the population studied beyond the obesity-centered framing of GLP-1 longevity claims. It does not establish that the association is independent of weight loss or that GLP-1 drugs extend lifespan in otherwise healthy lower-BMI adults; no safety results or new evidence of trend spread are supplied.

Source

Link

Briefing card

Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27&#x2009;kg/m: A Target Trial Emulation.
Stage: observational · pubmed · 25-aug-2026

If you have type 2 diabetes and a BMI below 27 kg/m², this observational study linked GLP-1 receptor agonist use to lower heart failure risk than DPP-4 inhibitors, SGLT2 inhibitors, or usual care, without proving a causal benefit.

In adults with type 2 diabetes and BMI below 27 kg/m², GLP-1 receptor agonist use was consistently associated with reduced heart failure risk compared to DPP-4 inhibitors, SGLT2 inhibitors, and usual care.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1111/dom.71266

build build 880 · 2bcef25 · 2026-11-18